News | January 04, 2022
Combination of Covishield-Covaxin more effective: AIG hospital study
The first pilot study from India analyzing Covaxin-Covishield mixed doses
The first pilot study from India analyzing Covaxin-Covishield mixed doses
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
Flattish volume growth and subdued new launches were key factors for last month
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Effectiveness of Covaxin against the Omicron variant is currently being studied
Subscribe To Our Newsletter & Stay Updated
